Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Cardiff Oncology, Inc.NASDAQ: CRDF

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $11.58M.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.9M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$11.58M+18.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +18.8% is the 2nd highest of 7, against a peer median of -89.2%.
  • Cost of revenue amounts to 2205.7% of revenue for CRDF, versus a peer median of 5.1%.
CRDF Competitors
Cost of Revenue for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRDFCardiff Oncology, Inc.LTM Mar 2026$11.58M USD+18.8%—2205.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF-92.3%-62.9%—
PEPGPepGen Inc.LTM Mar 2026$1.72M USD+351.6%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$289K USD-75.2%+2.2%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$161K USD——5.1%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$149K USD-99.1%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$95K USD——5.3%
FBRXForte Biosciences, Inc.LTM Mar 2026$6K USD-86.0%——
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
Peer median (excluding CRDF) —-89.2%-30.4%5.1%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue359K386K488K683K593K
Cost of Revenue00000
Gross Profit359K386K488K683K593K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development17.38M27.11M32.86M36.85M35.33M
Selling, General & Admin11.84M13.18M13.04M12.48M14.22M
Operating Expenses29.21M40.29M45.9M49.33M49.55M
Depreciation & Amortization451K236K398K404K904K
EBITDA(27.84M)(38.47M)(41.04M)(45.03M)(44.95M)
EBITDA Margin-7754.9%-9965.8%-8410.5%-6592.5%-7579.6%
Operating Income(28.86M)(39.9M)(45.41M)(48.65M)(48.96M)
Operating Margin-8037.6%-10337.3%-9305.7%-7123.1%-8256.3%
Interest Income264K1.58M4.07M3.26M3.1M
Interest Expense00000
Other Income / Expenses564K1.2M3.97M3.22M3.11M
Income Before Tax(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Pre-Tax Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
Income Tax Expense00000
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Net Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
EPS (Basic)(0.73)(0.89)(0.93)(0.95)(0.69)
EPS (Diluted)(0.73)(0.89)(0.93)(0.95)(0.69)
Weighted Avg Shares39.03M43.6M44.68M47.65M66.84M
Weighted Avg Shares (Diluted)39.03M43.6M44.68M47.65M66.84M

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.